readthroughSign in
Jun 29, 2026Trial update4 fact check notes

Rhythm Pharmaceuticals is collaborator on new German real-world setmelanotide study in BBS

A Phase 4 observational study tracking setmelanotide outcomes in Bardet-Biedl Syndrome patients has been registered, with Rhythm Pharmaceuticals listed as collaborator.

The week's sole registry update for Rhythm Pharmaceuticals involves a real-world data study on its approved MC4R agonist therapy.

  • A Phase 4 observational study called "REAL-MC4" (NCT07674290) is sponsored by Tom Hühne, with Rhythm Pharmaceuticals listed as a collaborator, and is being run at University Hospital Essen in Germany. The study is tracking setmelanotide's real-world effectiveness, safety, treatment persistence, metabolic outcomes, and patient-reported outcomes in Bardet-Biedl syndrome and related genetic obesity disorders1. Recruiting status is listed with an actual start date of 2023-01-011 and enrollment estimated at 200 participants1, with primary completion estimated for 2030-12-31.

Fact check notes

  • ImpreciseA Phase 4 observational study called "REAL-MC4" (NCT07674290)The source's Design section explicitly lists Study type as 'interventional', not observational, despite the study's title mentioning both 'Observational' and 'Interventional'. Calling it purely an 'observational study' contradicts the structured Study type field.
  • ImpreciseRhythm Pharmaceuticals is collaborator on new German real-world setmelanotide study in BBSCollaborator and German site details are accurate, but calling it a 'new' study is arguable since the actual start date is 2023-01-01, well before the 2026 registry posting.
  • Checker's noteThe entry labels the study as 'observational' while the source's structured Design section explicitly states Study type: interventional, phase4, creating a contradiction with the source's clear metadata field.
  • Checker's noteThe headline calls the study 'new' despite its actual start date being 2023-01-01, three years before the registry was first posted (2026-06-29), which may overstate novelty.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.